1-Jahres-Chart
5-Tage-Chart
| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 7,350 | 7,600 | 16.08. | |
| 7,300 | 7,550 | 14.08. |
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 03:17 | HENLIUS Reaches Global Strategic Partnership With Sandoz, Invoiceable Amt Expected to Reach USD100.5M This Year | 2 | AASTOCKS | ||
| 02:03 | Adhoc: Sandoz Group AG: Sandoz announces strategic collaboration with Henlius on up to 10 biosimilars, further expanding industry-leading pipeline | 472 | EQS Group (EN) | Sandoz Group AG / Key word(s): Agreement/Strategic Company Decision
Sandoz announces strategic collaboration with Henlius on up to 10 biosimilars, further expanding industry-leading pipeline... ► Artikel lesen | |
| 02:00 | HENLIUS (02696): INSIDE INFORMATION ANNOUNCEMENT - STRATEGIC COLLABORATION WITH SANDOZ | 1 | HKEx | ||
| 03.08. | HENLIUS (02696): DATE OF BOARD MEETING | 1 | HKEx | ||
| 31.07. | HENLIUS (02696): VOLUNTARY ANNOUNCEMENT - THE INVESTIGATIONAL NEW DRUG APPLICATION FOR CLINICAL TRIAL OF HLX43 FOR INJECTION (AN ANTIBODY-DRUG CONJUGATE ... | 1 | HKEx | ||
| 30.07. | HENLIUS HLX3902 Injection Completes First Patient Dosing in Phase 1 Clinical Study in China | 3 | AASTOCKS | ||
| 30.07. | HENLIUS (02696): VOLUNTARY ANNOUNCEMENT - THE FIRST PATIENT HAS BEEN DOSED IN A PHASE 1 CLINICAL STUDY OF HLX3902 INJECTION (STEAP1XCD3XCD28 TRISPECIFIC ... | - | HKEx | ||
| SHANGHAI HENLIUS BIOTECH Aktie jetzt für 0€ handeln | |||||
| 17.07. | HENLIUS (02696): GRANTS OF OPTIONS AND RSUS | 1 | HKEx | ||
| 16.07. | HENLIUS (02696): VOLUNTARY ANNOUNCEMENT - THE GLOBAL FIRST PATIENT HAS BEEN DOSED IN AN INTERNATIONAL MULTI-CENTER PHASE 1 CLINICAL STUDY OF NIVOLUMAB ... | 1 | HKEx | ||
| 10.07. | HENLIUS (02696): VOLUNTARY ANNOUNCEMENT - THE INVESTIGATIONAL NEW DRUG APPLICATION FOR THE PHASE 1 CLINICAL TRIAL OF HLX37 (RECOMBINANT HUMANISED ANTI-PD-L1 ... | 1 | HKEx | ||
| 08.07. | HENLIUS (02696): VOLUNTARY ANNOUNCEMENT - THE FIRST PATIENT HAS BEEN DOSED IN A PHASE 1 CLINICAL STUDY OF CETUXIMAB INJECTION BIOSIMILAR HLX05-N (RECOMBINANT ... | - | HKEx | ||
| 30.06. | HENLIUS (02696): VOLUNTARY ANNOUNCEMENT - THE FIRST PATIENT HAS BEEN DOSED IN A PHASE 1 CLINICAL STUDY OF HLX48 FOR INJECTION (AN ANTIBODY-DRUG CONJUGATE ... | 1 | HKEx | ||
| 25.06. | HENLIUS (02696): VOLUNTARY ANNOUNCEMENT - THE FIRST PATIENT IN THE UNITED STATES HAS BEEN DOSED IN AN INTERNATIONAL MULTICENTER PHASE 1 CLINICAL STUDY ... | 1 | HKEx | ||
| 25.06. | HENLIUS (02696): VOLUNTARY ANNOUNCEMENT - THE EUROPEAN COMMISSION (EC) HAS APPROVED A NEW INDICATION FOR SERPLULIMAB INJECTION (TRADE NAME IN CHINESE ... | - | HKEx | ||
| 23.06. | Organon and Henlius launch Prolia and Xgeva biosimilars in Canada | 2 | Seeking Alpha | ||
| 17.06. | HENLIUS (02696): VOLUNTARY ANNOUNCEMENT - THE PHASE 1 CLINICAL TRIAL OF HLX3902 INJECTION (STEAP1XCD3XCD28 TRISPECIFIC ANTIBODY) FOR THE TREATMENT OF ... | 1 | HKEx | ||
| 17.06. | HENLIUS (02696): VOLUNTARY ANNOUNCEMENT - HANBEIYOU (PERTUZUMAB INJECTION) PASSING GMP COMPLIANCE INSPECTION | - | HKEx | ||
| 16.06. | HENLIUS (02696): VOLUNTARY ANNOUNCEMENT - THE PHASE 2 CLINICAL TRIAL OF HLX43 FOR INJECTION (AN ANTI-PD-L1 ANTIBODY-DRUG CONJUGATE) IN COMBINATION WITH ... | - | HKEx | ||
| 16.06. | HENLIUS (02696): VOLUNTARY ANNOUNCEMENT - AN INTERNATIONAL MULTI-CENTER PHASE 3 CLINICAL STUDY OF RECOMBINANT ANTI-VEGF HUMANISED MONOCLONAL ANTIBODY ... | - | HKEx | ||
| 11.06. | HENLIUS (02696): NEXT DAY DISCLOSURE RETURNS | 3 | HKEx |
1 2 3 4 5 Weiter >>
84 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| VERA THERAPEUTICS | 31,630 | 0,00 % | Goldman Sachs lowers Vera Therapeutics stock price target to $80 | ||
| SUMMIT THERAPEUTICS | 13,350 | 0,00 % | Could Arcus Biosciences (RCUS) and Summit Therapeutics (SMMT)'s Cancer Drug Partnership Create a New Treatment Standard? | ||
| QIAGEN | 37,290 | -0,98 % | DAX Gewinner am Montag: Qiagen Aktie | Kursentwicklung und Chartanalyse | ||
| APOGEE THERAPEUTICS | 134,56 | +0,01 % | Apogee Therapeutics: Apogee Reports Second Quarter 2026 Financial Results and Recent Corporate and Pipeline Updates | AbbVie to acquire Apogee for $135.11 per share in cash for total equity value of approximately $10.9 billion, positioning differentiated immunology portfolio to reach more patients worldwide Positive... ► Artikel lesen | |
| ERASCA | 18,390 | 0,00 % | Erasca, Inc.: Erasca Reports Second Quarter 2026 Business Updates and Financial Results | Updated ERAS-0015 data in U.S. trial highlighted compelling monotherapy efficacy in 2L+ KRAS G12X PDAC and continued favorable tolerability, as well as further advancement of panitumumab CRC combination... ► Artikel lesen | |
| PRAXIS PRECISION MEDICINES | 367,40 | +0,16 % | Praxis Precision Medicines, Inc.: Praxis Precision Medicines Announces Extension Period for Relutrigine for Treatment of SCN2A and SCN8A Developmental and Epileptic Encephalopathies | FDA sets updated PDUFA date of December 27, 2026 BOSTON, June 29, 2026 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a fully integrated, leading central nervous system (CNS)... ► Artikel lesen | |
| AMYLYX PHARMACEUTICALS | 21,625 | -0,02 % | Biotech Stocks At 52-Week Highs - LH Rises With Genetic Testing Launch, DYN, SNDA, SLN, AMLX, | LONDON (dpa-AFX) - The following biotech stocks reached a 52-week high on July 27, 2026, driven by key catalysts including prospective clinical trial results, and the launch of new services.Dyne... ► Artikel lesen | |
| TANGO THERAPEUTICS | 25,610 | +0,04 % | Tango Therapeutics, Inc.: Tango Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Highlights | Company continues to prepare for late-stage clinical advancement of vopimetostat in combination with daraxonrasib for pancreatic cancer following positive Phase 1/2 data Phase 1/2 data from combination... ► Artikel lesen | |
| COGENT BIOSCIENCES | 37,950 | +0,05 % | Cogent Biosciences, Inc. - 10-Q, Quarterly Report | ||
| KYMERA THERAPEUTICS | 117,37 | 0,00 % | Kymera International Appoints Willson Ropp as Chief Executive Officer | Experienced specialty materials executive brings more than 30 years of leadership experience across global manufacturing, operational excellence, business integration, and long-term value... ► Artikel lesen | |
| CLIMB BIO | 16,340 | +0,06 % | Climb Bio, Inc. - 8-K, Current Report | ||
| CG ONCOLOGY | 75,10 | +0,09 % | CG Oncology Inc.: CG Oncology Reports Second Quarter 2026 Financial Results and Provides Business Updates | PIVOT-006 Phase 3 topline data evaluating cretostimogene monotherapy as an adjuvant therapy in intermediate-risk NMIBC anticipated in the near-termBLA completion for HR BCG-unresponsive NMIBC expected... ► Artikel lesen | |
| DYNE THERAPEUTICS | 25,690 | 0,00 % | Dyne Therapeutics, Inc.: Dyne Therapeutics Reports Second Quarter 2026 Financial Results and Recent Business Highlights | - Biologics License Application (BLA) for z-rostudirsen in exon 51 DMD accepted for review by FDA; Priority Review granted; PDUFA target action date set for January 21, 2027 - - Completed enrollment... ► Artikel lesen | |
| ARCUTIS BIOTHERAPEUTICS | 26,195 | 0,00 % | Arcutis Biotherapeutics, Inc.: Arcutis Expands Board of Directors with Appointment of Chris Peetz | WESTLAKE VILLAGE, Calif., July 16, 2026 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovation in... ► Artikel lesen | |
| KINIKSA PHARMACEUTICALS | 76,69 | -0,08 % | Kiniksa auf Wachstumskurs: ARCALYST-Umsatz steigt, Pipeline wird ausgebaut |
SHANGHAI HENLIUS BIOTECH INC gehört der Branche Biotechnologie an. Der aktuelle Kurs liegt bei 7,300 Euro und damit -2,67 % im Minus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu SHANGHAI HENLIUS BIOTECH INC finden Sie auf Wallstreet Online.